Iron status influences mitochondrial disease progression in Complex I-deficient mice.
biochemistry
chemical biology
electron transport chain
iron overload
iron restriction
leigh syndrome
medicine
mitochondrial disease
mouse
neurometabolic
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
17 02 2023
17 02 2023
Historique:
received:
24
11
2021
accepted:
10
02
2023
pubmed:
18
2
2023
medline:
24
3
2023
entrez:
17
2
2023
Statut:
epublish
Résumé
Mitochondrial dysfunction caused by aberrant Complex I assembly and reduced activity of the electron transport chain is pathogenic in many genetic and age-related diseases. Mice missing the Complex I subunit NADH dehydrogenase [ubiquinone] iron-sulfur protein 4 (NDUFS4) are a leading mammalian model of severe mitochondrial disease that exhibit many characteristic symptoms of Leigh Syndrome including oxidative stress, neuroinflammation, brain lesions, and premature death. NDUFS4 knockout mice have decreased expression of nearly every Complex I subunit. As Complex I normally contains at least 8 iron-sulfur clusters and more than 25 iron atoms, we asked whether a deficiency of Complex I may lead to iron perturbations, thereby accelerating disease progression. Consistent with this, iron supplementation accelerates symptoms of brain degeneration in these mice, while iron restriction delays the onset of these symptoms, reduces neuroinflammation, and increases survival. NDUFS4 knockout mice display signs of iron overload in the liver including increased expression of hepcidin and show changes in iron-responsive element-regulated proteins consistent with increased cellular iron that were prevented by iron restriction. These results suggest that perturbed iron homeostasis may contribute to pathology in Leigh Syndrome and possibly other mitochondrial disorders. Iron is a mineral that contributes to many vital body functions. But as people age, it accumulates in many organs, including the liver and the brain. Excess iron accumulation is linked to age-related diseases like Parkinson’s disease. Too much iron may contribute to harmful chemical reactions in the body. Usually, the body has systems in place to mitigate this harm, but these mechanisms may fail as people age. Uncontrolled iron accumulation may damage essential proteins, DNA and fats in the brain. These changes may kill brain cells causing neurodegenerative diseases like Parkinson’s disease. Mitochondria, the cell’s energy-producing factories, use and collect iron inside cells. As people age, mitochondria fail, which is also linked with age-related diseases. It has been unclear if mitochondrial failure may also contribute to iron accumulation and associated diseases like Parkinson’s. Kelly et al. show that mitochondrial dysfunction causes iron accumulation and contributes to neurodegeneration in mice. In the experiments, Kelly et al. used mice with a mutation in a key-iron processing protein in mitochondria. These mice develop neurodegenerative symptoms and die early in life. Feeding the mice a high-iron diet accelerated the animals’ symptoms. But providing them with an iron-restricted diet slowed their symptoms and extended their lives. Low-iron diets also slowed iron accumulation in the animal’s liver and reduced brain inflammation. The experiments suggest that mitochondrial dysfunction contributes to both iron overload and brain degeneration. The next step for scientists is understanding the processes leading to mitochondrial dysfunction and iron accumulation. Then, scientists can determine if they can develop treatments targeting these processes. This research might lead to new treatments for Parkinson’s disease or other age-related conditions caused by iron overload.
Autres résumés
Type: plain-language-summary
(eng)
Iron is a mineral that contributes to many vital body functions. But as people age, it accumulates in many organs, including the liver and the brain. Excess iron accumulation is linked to age-related diseases like Parkinson’s disease. Too much iron may contribute to harmful chemical reactions in the body. Usually, the body has systems in place to mitigate this harm, but these mechanisms may fail as people age. Uncontrolled iron accumulation may damage essential proteins, DNA and fats in the brain. These changes may kill brain cells causing neurodegenerative diseases like Parkinson’s disease. Mitochondria, the cell’s energy-producing factories, use and collect iron inside cells. As people age, mitochondria fail, which is also linked with age-related diseases. It has been unclear if mitochondrial failure may also contribute to iron accumulation and associated diseases like Parkinson’s. Kelly et al. show that mitochondrial dysfunction causes iron accumulation and contributes to neurodegeneration in mice. In the experiments, Kelly et al. used mice with a mutation in a key-iron processing protein in mitochondria. These mice develop neurodegenerative symptoms and die early in life. Feeding the mice a high-iron diet accelerated the animals’ symptoms. But providing them with an iron-restricted diet slowed their symptoms and extended their lives. Low-iron diets also slowed iron accumulation in the animal’s liver and reduced brain inflammation. The experiments suggest that mitochondrial dysfunction contributes to both iron overload and brain degeneration. The next step for scientists is understanding the processes leading to mitochondrial dysfunction and iron accumulation. Then, scientists can determine if they can develop treatments targeting these processes. This research might lead to new treatments for Parkinson’s disease or other age-related conditions caused by iron overload.
Identifiants
pubmed: 36799301
doi: 10.7554/eLife.75825
pii: 75825
pmc: PMC10030112
doi:
pii:
Substances chimiques
Iron
E1UOL152H7
Electron Transport Complex I
EC 7.1.1.2
Ndufs4 protein, mouse
0
Banques de données
Dryad
['10.5061/dryad.xpnvx0khb']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : F32 NS110109
Pays : United States
Organisme : NIH HHS
ID : R01 NS098329
Pays : United States
Organisme : NIH HHS
ID : P30 AG013280
Pays : United States
Informations de copyright
© 2023, Kelly et al.
Déclaration de conflit d'intérêts
CK, RC, VH, CB, JW, SH, NH, HK, AZ, JS, YP, MK, AG No competing interests declared
Références
Elife. 2023 Feb 17;12:
pubmed: 36799301
Curr Med Chem. 2005;12(10):1161-208
pubmed: 15892631
Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203
pubmed: 8695634
Cell. 2006 Jun 30;125(7):1241-52
pubmed: 16814712
Sci Adv. 2021 May 26;7(22):
pubmed: 34039609
Nat Rev Neurosci. 2004 Nov;5(11):863-73
pubmed: 15496864
Pediatr Nephrol. 1995 Aug;9(4):407-11
pubmed: 7577396
Free Radic Biol Med. 1995 Feb;18(2):321-36
pubmed: 7744317
EBioMedicine. 2020 Jun;56:102784
pubmed: 32454403
Mol Genet Metab. 2020 Jun;130(2):118-132
pubmed: 32331968
Antioxid Redox Signal. 2009 Sep;11(9):2083-94
pubmed: 19290777
J Biochem Biophys Methods. 2004 Mar 31;58(3):239-51
pubmed: 15026210
J Hum Genet. 2008;53(6):554-558
pubmed: 18386115
Science. 2013 Dec 20;342(6165):1524-8
pubmed: 24231806
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Science. 2003 May 9;300(5621):931-6
pubmed: 12738850
PLoS One. 2014 Jun 04;9(6):e98072
pubmed: 24896637
Neurobiol Dis. 2015 Sep;81:66-75
pubmed: 25771171
Cell. 2014 Nov 6;159(4):709-13
pubmed: 25417146
Biochim Biophys Acta. 2005 Sep 25;1741(3):246-52
pubmed: 16051470
Cell Metab. 2008 Apr;7(4):312-20
pubmed: 18396137
Ann Neurol. 2001 Mar;49(3):377-83
pubmed: 11261513
Biochem Biophys Res Commun. 2011 Jun 3;409(2):241-6
pubmed: 21570952
Lancet. 1998 Feb 14;351(9101):490-3
pubmed: 9482441
Blood Cells Mol Dis. 2002 Nov-Dec;29(3):444-50
pubmed: 12547234
Annu Rev Genet. 2005;39:359-407
pubmed: 16285865
Front Genet. 2017 Sep 01;8:113
pubmed: 28919908
Annu Rev Biochem. 2013;82:551-75
pubmed: 23527692
Nat Genet. 2001 Sep;29(1):57-60
pubmed: 11528392
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4241-E4250
pubmed: 28483998
Medicine (Baltimore). 2020 Jan;99(5):e18634
pubmed: 32000367
Metallomics. 2017 Aug 16;9(8):1028-1046
pubmed: 28620665
Cell. 2010 Jul 9;142(1):24-38
pubmed: 20603012
Genetics. 2013 Mar;193(3):677-713
pubmed: 23463800
Future Med Chem. 2010 Jan;2(1):51-64
pubmed: 20161623
Metallomics. 2009;1(4):292-311
pubmed: 21305127
iScience. 2020 Jul 24;23(7):101284
pubmed: 32623334
Transl Med Aging. 2017 Oct;1:1-4
pubmed: 32219192
Lancet Neurol. 2014 Oct;13(10):1045-60
pubmed: 25231526
Biometals. 2007 Jun;20(3-4):675-82
pubmed: 17225062
Cell. 2012 Mar 16;148(6):1145-59
pubmed: 22424226
Science. 2017 May 12;356(6338):608-616
pubmed: 28495746
Nat Metab. 2020 Dec;2(12):1472-1481
pubmed: 33324011
Cell Metab. 2019 Oct 1;30(4):824-832.e3
pubmed: 31402314
Biometals. 2011 Oct;24(5):785-809
pubmed: 21479832
Mol Aspects Med. 2001 Feb-Apr;22(1-2):1-87
pubmed: 11207374
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10771-8
pubmed: 7971961
Science. 2015 Dec 4;350(6265):1191-3
pubmed: 26785476
Methods Mol Biol. 2021;2277:143-155
pubmed: 34080150
Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2202-2209
pubmed: 28502703
Science. 2016 Apr 1;352(6281):54-61
pubmed: 26917594
Sci Rep. 2019 Feb 28;9(1):3073
pubmed: 30816177
Am J Hum Genet. 2002 Oct;71(4):863-76
pubmed: 12215968
Hepatology. 2011 Feb;53(2):437-47
pubmed: 21274865